PAF is a potent in ammatory compound known to stimulate the release of various cytokines involved in rheumatic diseases. Elevated blood PAF levels are reported in these patients. We report that serum PAF acetylhydrolase activity (AHA) levels are decreased in patients with rheumatoid arthritis or osteoarthritis as compared to healthy controls. Serum and synovial uid AHA levels were correlated in these patients. The present study suggests the potential role of AHA in controling systemic and/or local PAF levels in patients with rheumatic diseases.
Introduction
Platelet-activating factor (PAF), a phospholipid molecule with potent in ammatory activities, is involved in several in ammatory ailments in man. 1 Thus, regulating PAF levels is of importance since elevated concentrations of PAF could result in pathological effects. 1 Blood PAF levels are regulated by an acetylhydrolase activity (AHA) found in plasma and serum. 2 PAF is present in blood and synovial uid of patients with various arthropathies with higher concentrations in rheumatoid arthritis. 3 It is reported that these patients have higher serum AHA levels than healthy controls, 4 a result that does not t well with their elevated blood PAF levels. Contradictory results are also reported concerning the correlation between AHA levels in synovial uid and serum of rheumatoid arthritis patients. 4, 5 In order to clarify these points, we have assessed AHA in the serum and synovial uid of patients with rheumatoid arthritis and osteoarthritis.
Patients and Methods
Samples were obtained from patients presenting active disease and from healthy individuals according to the Helsinki recommendations. Fifty four patients had a rheumatoid arthritis according to the American Rheumatism Association criteria. The sex ratio (M/F) was 0.5 and the average age was 61.2 years (range 27 ±75). Twenty six patients had a symptomatic osteoarthritis; the sex ratio in this group was 1 and the average age was 67.7 years (range 45 ±75). Seventy four healthy individuals served as controls; the sex ratio (M/F) was 2.2 and the average age was 50.7 years (range 20 ±98). Sera (collected from all patients and controls) and synovial uids (collected from 12 and 13 patients with rheumatoid arthritis and osteoarthritis, respectively) were stored at -808 C until assay of AHA.
AHA was measured by the degradation of [ 3 H]PAF as previously reported. 6, 7 Brie y 1 3 10 5 dpm of 1-0-alkyl-2-[ 3 H]acetyl-glycerophosphocholine ([ 3 H]acetyl-PAF, 10 Ci/ mmol, NEN), 0.1 mM PAF, HEPES buffer (pH 7.8) in a nal volume of 450 ml, and 50 ml diluted serum (1:50 dilution in HEPES buffer) were incubated for 20 min at 37 8 C. The reaction was stopped with 100 ml BSA (10%) and 400 ml trichloracetic acid (20%). Samples were centrifuged (1500 3 g, 15 min) and supernatants counted in a liquid scintillation counter. Results are expressed as nanomoles PAF degraded per ml of serum or synovial uid (nmol/ min/ ml) as means of duplicate determinations. The variation between duplicates was less than 6%.
Differences between groups were assessed by Mann ±Whitney U-test. Serum and synovial uid AHA levels were correlated by linear regression analysis.
Results and Discussion
Serum AHA levels were signi cantly (P < 0·0004) decreased in patients with rheumatoid arthritis (49·7 2·2 nmol/ min/ ml) or osteoarthritis (62·8 3·2 nmol/ min/ ml) as compared to healthy controls (74·3 1·9 nmol/ min/ ml) (Fig. 1) . AHA levels in synovial uid were not signi cantly (P = 0·91) different in patients with rheumatoid arthritis (41·8 5·5 nmol/ ml/ min) and osteoarthritis (44·9 8·0 nmol/ ml/ min). Serum and synovial uid AHA levels were correlated in patients with rheumatoid arthritis (r = 0·83, P = 0·0016) and osteoarthritis (r = 0·57, P = 0·04).
Serum AHA levels in our healthy individuals were similar to previous reports by us and others.
7 -11 As already documented, 4, 5 we found that AHA levels in synovial uid were not different in patients with rheumatoid arthritis and osteoarthritis. In our study, AHA levels in synovial uid were correlated with those in the serum. In contrast to a previous report, 4 we found a signi cant decrease of serum AHA levels in patients with rheumatic diseases especially in those with rheumatoid arthritis. This result might, in part, explain the elevated circulating blood PAF levels reported in these patients. 3 PAF is a potent in ammatory compound known to stimulate the release of various cytokines (such as IL-1, IL-6 and TNF-a) involved in rheumatoid arthritis. 12, 13 Thus, the present study suggests the potential role of AHA in controlling systemic and/or local PAF levels in patients with rheumatic diseases. 
